



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

IOLCP/CGC/2014

14 August 2014

The General Manager
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

The General Manager
Bombay Stock Exchange Limited.
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai

Sub: Un-audited Financial Results

Dear Sir,

Pursuant to Clause 41 of the Listing Agreement, we are enclosing herewith copy of the Un-audited Financial Results and Segment Report for the quarter ended 30 June 2014 alongwith the Limited Review Certificate of the Statutory Auditor.

This is for your information and record please.

Thanking you

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited



Authorised Signatory

Encl : 1. Un-audited Financial Results & Segment Report
2. Limited review certificate

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292

CIN:-L24116PB1986PLC007030




IOL CHEMICALS AND PHARMACEUTICALS LIMITED

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2014

Rs. in Lacs

Sr. No.	Particulars	Quarter Ended			Year ended
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		30.06.2014	31.03.2014	30.06.2013	31.03.2014
1	Income from Operations				
a	Net Sales / Income from operations (net of excise duty)	12086.25	13063.80	13914.34	56350.13
b	Other Operating Income	32.07	34.97	90.27	128.87
	Total income from Operations (net)	12118.32	13098.77	14004.61	56479.00
2	Expenses				
a	Cost of materials consumed	8146.38	9133.17	9243.66	39791.52
b	Purchase of stock-in-trade	0.00	0.00	0.00	0.00
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(706.25)	(631.22)	74.48	(2799.02)
d	Employee benefits expense	649.37	722.64	650.24	2707.70
e	Depreciation and amortisation expense	781.52	788.81	784.57	3163.03
f	Other expenditure	1542.24	1488.83	1591.19	7074.95
	Total Expenses	10413.26	11502.23	12344.14	49938.18
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	1705.06	1596.54	1660.47	6540.82
4	Other Income	0.45	0.45	0.45	1.80
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	1705.51	1596.99	1660.92	6542.62
6	Finance costs	1514.67	1499.20	1535.37	6034.39
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	190.84	97.79	125.55	508.23
8	Exceptional Items	0.00	0.00	0.00	0.00
9	Profit (+) / Loss (-) from ordinary activities before tax (7+8)	190.84	97.79	125.55	508.23
10	Tax Expenses	65.72	16.76	43.06	178.29
11	Net Profit (+)/Loss (-) from ordinary activities after tax (9-10)	125.12	81.03	82.49	329.94
12	Extraordinary Item (net of tax expense)				
13	Net Profit (+)/Loss (-) for the period (11-12)	125.12	81.03	82.49	329.94
14	Paid-up equity share capital (Face value Rs. 10/- Per Share)	3816.16	2881.52	2615.12	2881.52
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				16042.49
16	Earning per share (before and after extraordinary item (Face value of Rs. 10/- each)				
	Basic	0.42	0.21	0.32	1.21
	Diluted	0.42	0.21	0.32	1.21
	Cash	3.13	3.24	3.38	13.11



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030

Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com

Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India

Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India


Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

PART-II SELECT INFORMATION FOR THE QUARTER ENDED 30 JUNE 2014

Sr. No.	Particulars	Quarter Ended			Year Ended
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		30.06.2014	31.03.2014	30.06.2013	31.03.2014
A	Particulars of Shareholding				
1	Public Shareholding				
	-- No of Shares	15762325	11776611	11776611	11776611
	-Percentage of Shareholding	41.30	40.87	45.03	40.87
2	Promoters and promoter group Shareholding				
	a) Pledged/Encumbered				
	- Number of shares		-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)		-	-	-
	- Percentage of shares (as a % of the total share capital of the company)		-	-	-
	b) Non-encumbered				
	- Number of shares	22399266	17038553	14374553	17038553
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	58.70	59.13	54.97	59.13
B	Particulars	3 months ended 30 June 2014			
	Investor Complaints				
1	Pending at the beginning of the quarter			NIL	
2	Received during the quarter			NIL	
3	Disposed of during the quarter			NIL	
4	Remaining unresolved at the end of the quarter			NIL	



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
 Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

Segment wise Revenue, Results and Capital Employed, under clause 41 of the Listing Agreement

Rs. in Lacs

Particulars	Quarter Ended			Year Ended
	unaudited			Audited
	30.06.2014	31.03.2014	30.06.2013	31.03.2014
1. Segment Revenue				
(Net sale/income)				
- Chemicals	6672.01	8225.93	8844.70	36729.04
- Drugs	6051.37	6607.09	7011.36	27502.84
- Unallocated	52.63	58.62	69.23	311.30
Total	12776.01	14891.64	15925.29	64543.18
Less : Inter segment revenue	657.69	1792.87	1920.68	8064.18
Net sales/income from operations	12118.32	13098.77	14004.61	56479.00
2. Segment Results				
Profit(+)/(loss)(-) before tax and interest from each segment)				
- Chemicals	(113.25)	(233.76)	(111.57)	71.69
- Drugs	1780.03	1823.58	1709.18	6246.95
Total	1666.78	1589.82	1597.61	6318.64
Less: Interest	1514.67	1499.20	1535.38	6034.39
Less: Other un-allocable expenditure net of unallocable income	(38.73)	(7.17)	(63.32)	(223.98)
Total Profit(+)/(loss) (-) before tax & Extraordinary Items	190.84	97.79	125.55	508.23
3. Capital Employed				
(Segment assets - Segment Liabilities)				
- Chemicals	10381.13	10452.27	5748.01	10452.27
- Drugs	11251.92	11349.49	10548.66	11349.49
- Unallocated	1098.17	337.13	1001.03	337.13
Total	22731.22	22138.89	17297.70	22138.89

NOTES:

- The above results have been reviewed by the Audit & Risk Management Committee and were considered and approved by the Board of the Directors at their meeting held on 14 August 2014.
- Consequent to the enactment of the Companies Act, 2013 (the Act) and its applicability for accounting periods commencing from 1st April 2014, the Company has recalculated the remaining useful life of fixed assets in accordance with provisions of Schedule II to the Act. In case of Fixed assets which have already completed their useful life in terms of Schedule II of the Act, the carrying value (net of residual value) of such assets as at 1st April 2014 amounting to Rs.99.20 Lacs (net of deferred tax) has been adjusted to Retained Earnings and in case of other fixed assets the carrying value (net of residual value) is being depreciated as per straight line method over the re-calculated remaining useful life. The depreciation and amortization expense charged for the quarter ended 30 June 2014 would have been lower by Rs.13.53 Lacs, had the company continued with the previously prescribed depreciation rates as per Schedule-XIV of Companies Act, 1956.
- During the quarter the Company has allotted 22,00,000 equity shares of Rs 10/- each at a premium of Rs 18/- per share to the non promoters and has also allotted 53,60,713 equity shares of Rs 10/- each at a premium of Rs 18/- per share to the promoters companies and 17,85,714 equity shares of Rs 10/- each at a premium of Rs 18/- per share to the non promoters on the redemption of non redeemable cumulative preference shares .
- Previous period's figures have been regrouped/ reclassified wherever necessary.
- Limited review of the above unaudited financial results of the Company in term of Clause 41 of the Listing Agreement has been carried out by the Statutory Auditors of the Company

For IOL Chemicals and Pharmaceuticals Limited

By order of the Board

 Vijay Kumar Garg
 Joint Managing Director
 DIN: 06510248

Place: Ludhiana
 Date: 14 August 2014

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
 Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292

REVIEW REPORT

To
The Board of Directors,
IOL Chemicals and Pharmaceuticals Limited
Ludhiana

1. We have reviewed the accompanying Statement of Unaudited financial results of IOL Chemicals and Pharmaceuticals Limited (the Company), for the Quarter ended 30th June, 2014 (the Statement), being submitted by the company pursuant to Clause 41 of the Listing Agreements with the Stock Exchanges except for the disclosure regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which has been traced from disclosures made by the Management and have not been reviewed by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the Accounting Standards issued under the Companies (Accounting Standards) Rules, 2006 which continue to apply as per section 133 of the Company's Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements, including the manner in which it is to be disclosed, or that it contains any material misstatement.

CERTIFIED TO BE TRUE COPY

Place: Ludhiana
Dated: 14th August, 2014

For IOL Chemicals and Pharmaceuticals Limited


Krishan Singla
Vice President & Company Secretary

For S.C. Vasudeva & Co.
Chartered Accountants
Registration No.00235N




(Sanjiv Mohan)
Partner
M. No. 86066